DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
ZICONOTIDE ACETATE
Search structure
Trade Names:
PRIALT
Synonyms:
Prialt
Ziconotide acetate
Status:
Approved (2004)
Entry Type:
Protein
Molecule Category:
Salt
UNII:
T2I226K69M
Parent Compound:
ZICONOTIDE
Pharmacology
Action
Mechanism of Action
Reference
BLOCKER
Voltage-gated N-type calcium channel alpha-1B subunit blocker
PubMed
FDA
Indications
Mesh Heading
Maximum Phase
Mesh ID
Reference
Related Entries
Parent
ZICONOTIDE
Adverse Reactions
SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Nervous system disorders
18.4
General disorders and administration site conditions
18.27
Psychiatric disorders
16.65
Musculoskeletal and connective tissue disorders
6.55
Gastrointestinal disorders
5.82
Injury, poisoning and procedural complications
5.73
Product issues
4.87
Skin and subcutaneous tissue disorders
4.22
Cardiac disorders
3.34
Vascular disorders
2.86
Respiratory, thoracic and mediastinal disorders
2.38
Cross References
Resources
Reference
ChEMBL
CHEMBL1795072
FDA SRS
T2I226K69M
PubChem
72941949
CONTENTS
Structure
Indications
Related Entries
Adverse Reactions
Cross References
×
Active Pharmaceutical Ingredients (APIs)
Scaffolds
Exact
Similarity
SubStructure
Threshold (%) >=
70